1. Bioactive solanidane steroidal alkaloids from Solanum lyratum.
- Author
-
Wu T, Du X, Liu HH, Liu LY, Yang YK, Wang SJ, and Duan CL
- Subjects
- Humans, A549 Cells, Molecular Structure, Antineoplastic Agents, Phytogenic pharmacology, Antineoplastic Agents, Phytogenic isolation & purification, Cell Movement drug effects, Phytochemicals pharmacology, Phytochemicals isolation & purification, Solanaceous Alkaloids pharmacology, Solanaceous Alkaloids isolation & purification, Signal Transduction drug effects, Alkaloids pharmacology, Alkaloids isolation & purification, China, Solanum chemistry
- Abstract
Six previously unreported solanidane steroidal alkaloids, namely lyrasolanosides A-F, were isolated from Solanum lyratum. In addition, five known steroidal alkaloids were also identified. The structures of these compounds were determined through the use of NMR, HRESIMS,UV, IR and ECD analysis. To assess their bioactivities, the cytotoxic effects of the six previously unreported compounds were evaluated on A549 cells. The results revealed that lyrasolanoside B (2) exhibited the highest potency among them. Lyrasolanoside B (2) exhibited significant inhibition of cell migration, invasion, and adhesion dramatically. Mechanistically, it was found to suppress the activity of JAK2/STAT3 signaling pathway by downregulating the expression of phosphorylated JAK2/STAT3 in an exosome-dependent manner. In addition, lyrasolanoside B (2) was found to significantly upregulate the expression of E-cadherin and downregulate the expression of N-cadherin and vimentin. These findings indicate that lyrasolanoside B (2) inhibits the metastasis of A549 cells by suppressing exosome-mediated EMT. These findings suggest that lyrasolanoside B (2) may inhibit the metastasis of lung cancer by regulating A549-derived exosomes., Competing Interests: Declaration of competing interest The authors declare no conflict interest., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF